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ORIGINAL ARTICLE
Long-term follow-up after bronchoscopic lung volume reduction
treatment with coils in patients with severe emphysema
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DIRK-JAN SLEBOS1,2
1Department of Pulmonary Diseases and 2Groningen Research Institute for Asthma and COPD, University of Groningen,
University Medical Center Groningen, Groningen, The Netherlands
ABSTRACT
Background and objective: Bronchoscopic lung
volume reduction coil (LVR-coil) treatment has been
shown to be safe and clinically effective in patients with
severe emphysema in the short term; however, long-
term safety and effectiveness has not been evaluated.
The aim of this study was to investigate the long-term
safety and effectiveness of LVR-coil treatment in
patients with severe emphysema.
Methods: Thirty-eight patients with severe emphy-
sema (median age is 59 years, forced expiratory volume
in 1 s is 27% predicted) who were treated in LVR-coil
clinical trials were invited for a voluntary annual visit.
Safety was evaluated by chest X-ray and recording
of adverse events and by efficacy by pulmonary
function testing, 6-min walk distance (6MWD) and
questionnaires.
Results: Thirty-five patients visited the hospital 1
year, 27 patients 2 years and 22 patients 3 years follow-
ing coil placement. No coil migrations were observed
on X-rays. At 1-year follow-up, all clinical outcomes sig-
nificantly improved compared with baseline. At 2
years, residual volume % pred, modified Medical
Research Council (mMRC) and the SGRQ score were
still significantly improved. At 3 years, a significant
improvement in mMRC score remained, with 40% of
the patients reaching the 6MWD minimal important
difference, and 59% for the St George’s Respiratory
Questionnaire (SGRQ) minimal important difference.
Conclusions: Follow-up of the patients treated with
LVR-coils in our pilot studies showed that the coil treat-
ment is safe with no late pneumothoraces, coil migra-
tions or unexpected adverse events. Clinical benefit
gradually declines over time; at 3 years post-treatment,
around 50% of the patients maintained improvement
in 6MWD, SGRQ and mMRC.
Clinical trial registration: NCT01220908 and NCT01328899
registered at ClinicalTrials.gov.
Key words: bronchoscopy and interventional technique, clini-
cal respiratory medicine, coil, emphysema, long-term follow-up.
Abbreviations: 6MWD, 6-min walk distance; 6MWT, 6-min
walk test; ATS, American Thoracic Society; BLVR, bronchoscopic
lung volume reduction; CV, collateral ventilation; FEV1, forced
expiratory volume in 1 s; LVR, lung volume reduction; LVRS, lung
volume reduction surgery; MID, minimal important difference;
mMRC, modified Medical Research Council; NETT, National
Emphysema Treatment Trial; SGRQ, St George’s Respiratory
Questionnaire.
INTRODUCTION
Bronchoscopic lung volume reduction (BLVR) is a
new minimally invasive treatment option for patients
with severe emphysema.1 BLVR with one-way
endobronchial valves, a ‘blocking’ device, is an effica-
cious method in a selected group of patients with
absence of collateral ventilation (CV).2,3 For the
majority of patients with severe emphysema, a BLVR
treatment that works independently of CV, a ‘non-
blocking’ device, must be used. One of the currently
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SUMMARY AT A GLANCE
This is the first study to investigate the safety and
efficacy of the lung volume reduction coil treat-
ment in the long term. At 3-year follow-up, this
treatment showed no long-term unexpected
adverse and device-related events, with clinical
benefit gradually declining over time.
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investigated non-blocking devices is the lung
volume reduction (LVR) coil (RePneu, PneumRx, Inc.,
Mountain View, CA, USA). This nitinol coil is
bronchoscopically delivered in both lungs in either
upper or lower lobe heterogeneous emphysema or
homogeneous emphysema,4,5 thereby compressing
diseased parenchyma and radially suspending
airways after placement in the lung.
To date, five studies investigating LVR-coil treat-
ment have been published.4–8 Four non-randomized
studies (n = 10, 11, 16 and 60 patients)4,6–8 and one
randomized study (24 controls and 23 treated
patients)5 showed that the procedure is feasible, safe
and well tolerated. Significant improvements in
quality of life, exercise capacity and pulmonary func-
tion were observed.4,5,7,8 Most studies had relatively
short follow-up times: 3 months,5,6 6 months4,8 and
one study up to 12 months after treatment.7 To our
knowledge, no study investigated a longer follow-up
time after LVR-coil treatment. This longer follow-up
time is needed to document both safety and effective-
ness of the procedure. In our hospital, we performed
two pilot studies investigating bronchoscopic LVR-
coil therapy, with treatments in 2009 and 2010.
The aim of this study is to investigate the safety and
effectiveness of LVR treatment with coils 1, 2 and 3
years post-treatment in patients with severe emphy-
sema who participated in pilot trials.
METHODS
Study population
Between April 2009 and November 2010, 38 patients
were treated with the LVR-coil at our institution,
in one of two pilot studies (NCT012209084 and
NCT013288997). The inclusion and exclusion criteria
for both can be found in Table S1. Both studies
were approved by the University Medical Center
Groningen Medical Ethics Committee, and all partici-
pants signed informed consents.
LVR-coil treatment
The LVR-coil procedure has been described before.4,6
In brief, the coils (RePneu, PneumRx Inc.) are made of
shape-memory nitinol wire, range in length from 70
to 200 mm to accommodate airways of different sizes
and are designed to compress the lung parenchyma.
The coils were bronchoscopically placed under
general anaesthesia in two sequential procedures
using fluoroscopy.
Study design
The follow-up period of both studies were 64 and 12
months7 after the second treatment. After completing
and exiting the study, patients were invited for a vol-
untary annual follow-up visit. Patients performed
pulmonary function measurements, 6-min walk test
(6MWT) and chest X-ray and completed question-
naires. Patients also had a consultation with a physi-
cian who reported the patient’s health status during
the past year.
Measurements
Spirometry, bodyplethysmography and the 6MWT
were performed using European Respiratory Society/
American Thoracic Society (ATS) guidelines.9–11
Health-related quality of life was measured by the
St George’s Respiratory Questionnaire (SGRQ)12 and
dyspnoea severity by the modified Medical Research
Council (mMRC) dyspnoea scale.13
Safety was measured by recording all adverse
events reported by the patients during the yearly
follow-up visits. The first X-ray after the treatment and
the last performed X-ray at final follow-up visit for all
participants were assessed for presence of coil migra-
tion (defined as displacement of the original post-
treatment coil position in the segment), atelectasis
and consolidation of tissue around the coils.
Pre-treatment decline in forced expiratory
volume in 1 s
All available spirometry results of the pre-treatment
years were collected from the patient’s own hospital,
serving as a reference of the expected decline in lung
function of our patients.
Lung transplantation
Two patients underwent a lung transplantation: one
patient at 1 year and the second patient at 4 years
post-treatment. Both patients gave permission for
histopathological examination of the explant. The
lung tissue was processed according to routine clini-
cal guidelines for confirmation of disease diagnosis
and assessment of any potential concurrent disease.
Haematoxylin and eosin stains were made on lung
sections after careful removal of the nitinol coils, and
representative sections were photographed and
unedited used for presentation in this study.
Statistical analysis
Due to non-normally distributed data, Wilcoxon
signed rank tests were performed to compare the
clinical characteristics at 1-, 2- and 3-year follow-up
against baseline and to compare if baseline charac-
teristics differed between responders and non-
responders at 3-year follow-up. For the responder
analyses, we counted the number of patients who
reached the earlier established minimal important
difference (MID) for forced expiratory volume in 1 s
(FEV1) (100 mL14 and 10%), RV (400 mL15), 6-min walk
distance (6MWD) (26 m16), and the SGRQ (4 points17).
The annual change in post-bronchodilator FEV1
before the treatment was derived from the slope of the
regression line for each patient’s individual FEV1
values measured at their own hospital. We only calcu-
lated the annual change in FEV1 of patients when at
least three FEV1 values were available. Paired sample
t-tests were performed to compare the difference in
the decline in FEV1 before and after the treatment.
P-values < 0.05 were considered statistically signifi-
cant. IBM-SPSS Statistics (v20) was used for statistical
analysis (IBM, Armonk, NY, USA).
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RESULTS
Patients
The baseline characteristics of the 38 patients are
shown in Table 1. One year after the treatment, 35
patients performed follow-up measurements, at 2
years 27 patients and at 3 years 22 patients (Fig. 1).
Safety
The adverse events are shown in Table 2. Six patients
(16%) died during the 3-year follow-up independent
of the treatment. The causes of death are reported in
Table 2. Two patients had a pneumothorax directly
after the coil procedure; however, no long-term
pneumothoraces occurred. Of the patients, 74%
reported a very mild haemoptysis just post-
procedure; only one patient reported spontaneous
settling of more severe haemoptysis at 3-year follow-
up. On the follow-up chest X-rays, we observed no coil
migrations, a segmental atelectasis was visible in 3
patients (8%) and consolidation of tissue around
some of the coils in 11 patients (29%) (see Fig. 2 for
the first X-ray post-procedure and the follow-up X-ray
at 3-year follow-up of two example patients).
Effectiveness
At 1-year follow-up, forced vital capacity, RV, RV/total
lung capacity, mMRC, 6MWD and SGRQ total score
were all significantly improved compared with base-
line. At 2-year follow-up, RV, mMRC and the SGRQ
total score were significantly improved when com-
pared with baseline. At 3-year follow-up, only the
mMRC was significantly improved compared with
baseline. The other clinical characteristics were
not significantly changed at 3 years compared with
baseline (Table 3).
The number of patients reaching the MID for FEV1
ranged from 20–30% (absolute change) to 30–40%
(relative change) throughout the 1- to 3-year follow-
up. The number of patients reaching the MID for RV
decreased during the 1- to 3-year follow-up, from 51%
to 19%. The number of patients reaching the MID for
6MWD decreased during the 1- to 3-year follow-up
from 57% to 40%. The number of patients reaching
the MID for SGRQ ranged from 50% to 60% through-
out the 1- to 3-year follow-up (Table 4). No differences
were found in baseline characteristics between
patients who reached the MID for SGRQ or 6MWD at
3-year follow-up compared to patients who did not
reach the MID.
Pre-treatment decline in FEV1
At least three previously performed FEV1 measure-
ments were available for 30/38 patients (79%). The
median number of available measurements was 9
(range 3–23) and the median number of days for the
first available measurement before treatment was
1989 days (range: 292–4376). The mean decline in
FEV1 before the LVR-coil treatment was −0.082 L/year
(standard deviation: 0.073). This was significantly dif-
ferent compared with the mean decline in FEV1
during study participation (mean decline: −0.036 L/
year, P = 0.018). The decline in FEV1 after more than 6
months of follow-up did not significantly differ com-
pared with the decline before the treatment (mean
decline: −0.060 L/year, P = 0.45) (Fig. 3).
Lung transplant explant evaluation
On gross macroscopic evaluation of the lung explants,
the coils could be identified in the main segmental
Figure 1 Flowchart of study participants. FU, follow-up; LVR,
lung volume reduction.
Table 1 Patient characteristics at baseline (n = 38)
Female, n (%) 28 (74)
Age, years 59.2 ± 7.7
BMI, kg/m2 24.9 (18.6–35.4)
Diagnosis emphysema, years 8.9 ± 3.5
Pack-years, years 34.7 ± 11.2
Heterogeneous emphysema, n (%) 35 (92)
FEV1, % predicted 27 (16–42)
GOLD stage, n (%)
III 13 (34)
IV 25 (66)
FVC, % predicted 81.5 ± 15.3
RV, % predicted 228 (155–341)
RV/TLC, ratio 0.61 (0.50–0.74)
mMRC score, n (%) 3.0 (2.0–4.0)
6MWD, meter 326 ± 94
SGRQ total score, points 63.2 (36.9–83.0)
Data are presented as number (%), mean ± standard deviation
or median (range).
6MWD, 6-min walk distance; BMI, body mass index; FEV1,
forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD,
Global Initiative for Chronic Obstructive Lung Disease; mMRC,
modified Medical Research Council; RV, residual volume; SGRQ,
St George’s Respiratory Questionnaire; TLC, total lung capacity.
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and sub-segmental airways. No vascular disruptions
were noticed, nor were there any abscess formations
in the coiled regions. Histopathological examination
revealed in both patients, besides presence of emphy-
sematous tissue, a thin, compressed capsule of tissue
around the imprints of the airways with a slight
inflammatory reaction. It was unclear whether these
changes represent pre-existing pathology in these
patients or if this is associated with device placement.
In the 1-year specimen, the presence of interstitial
fibrosis of alveolar septa with the device ‘capsule’ and
the surrounding alveolar parenchyma was visible. In
the 4-year specimen, the device imprint in the
airways was surrounded by a well-organized fibrous
capsule comprised of compressed, concentric rings of
stroma, and this was also found in the alveolar paren-
chyma, where the device imprint was in an area of
more dense fibrous tissue. No abundant inflamma-
tory reaction or infection was found in either explant
(see Fig. 4a–f).
Table 2 Number of reported adverse events
Baseline to
1-year







Death (%)† 1 (3) 3 (8) 2 (6)
Pneumothorax, yes (%) 2 (6) 0 (0) 0 (0)
Pneumonia, yes (%) 16 (46) 2 (7) 1 (5)
Hospitalization due to COPD exacerbation, yes (%) 18 (51) 10 (37) 8 (36)
Haemoptysis, yes (%) 0 (0) 0 (0) 1 (5)
† Percentages of patients who died were calculated based on the total number of patients at baseline.
Data are presented as number of patients (%). Causes of death (n = 6, time post-treatment): 1: 20 months (right upper lobe only);
pneumonia of the left lung with pseudomonas sepsis. 2: 10 months (right upper lobe only); end-stage COPD, complicated by a
osteoporotic Th6 fracture causing immobilization and severe pain. 3: 16 months (bilateral upper lobe); end-stage COPD with cor
pulmonale. 4: 16 months (bilateral upper lobe); sudden cardiac death not further specified. 5: 38 months (bilateral upper lobe);
myocardial infarction. 6: 35 months (bilateral upper lobe); end-stage COPD.
COPD, chronic obstructive pulmonary disease; FU, follow-up.
Figure 2 The first X-ray after the pro-
cedure and last available follow-up X-ray
of two example patients. (a) Directly after
the procedure in patient 1. (b) Three years
after the procedure in patient 1 without
any changes. (c) Directly after the pro-
cedure in patient 2. (d) Three years after
the procedure in patient 2, showing some
‘crowding’ of the coils in the left-upper
lobe resulting in volume reduction and a
better left hemi-diaphragm position.
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DISCUSSION
This was the first study that investigated the long-
term safety and effectiveness of bronchoscopic LVR
treatment with nitinol coils. In this trial, we followed
our first pilot study patients over the years and
showed that the treatment is safe in the long term.
After 1 year, the treatment was found to be clinically
effective compared with baseline, with a median
gradual decline of the clinical benefits over time, with
3-year follow-up approaching similar parameters to
the pre-treatment baseline for the overall group and
with a responder rate of 59% of the patients reaching
MID for SGRQ and 40% for 6MWD at 3 years.
In the 3-year follow-up of our pilot studies, patients
showed that the LVR-coil treatment was safe in the
long term. We witnessed no late pneumothoraces,
no coil migrations, no major haemoptysis, no major
infectious complications or unexpected adverse
device events and no treatment-related deaths. The
3-year survival in our group (84%) is in line with sur-
vival reports in the literature for comparable patient
populations. Lange et al. reported a 74.2% 3-year sur-
vival,18 and a 55–65% 3-year survival is reported when
using Collaborative Cohorts to Assess Multicom-
ponent Indices of COPD in Spain, Global Initiative for
Chronic Obstructive Lung Disease, or ATS/Body-Mass
Index, Airflow Obstruction, Dyspnea, and Exercise
Capacity Index in Chronic Obstructive Pulmonary
Disease severity criteria.19 Evaluation of post-lung
transplant-explanted lung tissue showed that the
proximal and mid portions of the coils can still be
found in the segmental and sub-segmental airways,
encapsulated by some fibrotic/organizing reaction,
with occasionally the most distal part of the coils being
encapsulated in the surrounding lung tissue, but with
no signs of serious inflammatory or infectious reac-
tions. These findings indicate that there is tendency of
the airways and lung tissue to slowly organize around
the coils, which might be due to local tissue stress,
compression and micromovements of the coils.
The treatment was beneficial for a large group of
patients after 1 year, with overall mean clinical
parameters returning to baseline values at 3 years.
Unfortunately, we did not have a control group in
which we could investigate the natural decline of
clinical parameters. However, the National Emphy-
sema Treatment Trial (NETT) study20 that investigated
lung volume reduction surgery (LVRS) in severe
emphysema patients with a median follow-up of 4.3
Table 3 Change in clinical characteristics at 1-, 2- and 3-year follow-up
Δ 1 Year FU to baseline
P-value
Δ 2 Year FU to baseline
P-value
Δ 3 Year FU to baseline
P-valuen = 35 n = 27 n = 22
FEV1, L 0.2 (−0.2 to 0.45) 0.171 −0.04 (−0.26 to 0.36) 0.809 −0.05 (−0.39 to 0.39) 0.664
FEV1, % predicted 1 (−6 to 20) 0.080 −1.0 (−9.0 to 17.0) 0.949 0 (−14 to 19) 0.747
FVC, L 0.04 (−0.39 to 1.13) 0.060 −0.02 (−0.85 to 1.11) 0.597 0.04 (−0.56 to 0.91) 0.723
FVC, % predicted 3 (−12 to 44) 0.014 1.0 (−25 to 44) 0.741 6 (−18 to 38) 0.169
RV, L −0.32 (−1.88 to 0.68) <0.001 −0.14 (−1.57 to 0.92) 0.093 0.07 (−1.67 to 1.41) 0.629
RV, % predicted −21.0 (−91.0 to 32.0) <0.001 −10.0 (−83 to 43) 0.012 −2 (−89 to 57) 0.509
RV/TLC, ratio −3.55 (−21.3 to 5.7) <0.001 −0.23 (−18.6 to 10.3) 0.428 1.49 (−19.0 to 12.5) 0.664
mMRC, score 0 (−3 to 2) 0.007 0.0 (−3.0 to 1.0) 0.007 −0.5 (−3 to 1) 0.039
6MWD, m 31.0 (−110 to 185) 0.010 −12.0 (−140 to 238) 0.696 −31.5 (−120 to 177) 0.970
SGRQ, total score −4.2 (−44.0 to 13.1) 0.005 −8.0 (−39.9 to 20.4) 0.032 −7.2 (−29.6 to 21.2) 0.101
Data are presented as median (range) (change between follow-up and baseline) and P-values. Baseline and follow-up measurements
were compared with Wilxocon signed-rank test (significant P-values are shown in bold).
6MWD, 6-min walk distance; FEV1, forced expiratory volume in 1 s; FU, follow-up; FVC, forced vital capacity; mMRC, modified Medical
Research Council; RV, residual volume; SGRQ, St George’s Respiratory Questionnaire; TLC, total lung capacity.
Table 4 Responder analysis
6-Month FU (n = 35) 1-Year FU (n = 35) 2-Year FU (n = 27) 3-Year FU (n = 22)
Δ FEV1 ≥ 100 mL (%) 11 (31) 8 (23) 5 (19) 7 (33)‡
Δ FEV1 ≥ 10% (%) 17 (49) 11 (31) 9 (33) 8 (38)‡
Δ RV ≤ 400 mL (%) 18 (51) 14 (40) 8 (30) 4 (19)‡
Δ 6MWD ≥ 26 m (%) 20 (57) 20 (57) 7 (27)† 8 (40)§
Δ SGRQ ≤ 4 points (%) 22 (63) 18 (51) 17 (63) 13 (59)
† n = 26; ‡ n = 21; § n = 20.
Data are presented as n (%).
Δ, delta compared with baseline; 6MWD, 6-min walk distance; FEV1, forced expiratory volume in 1 s; FU, follow-up; FVC, forced vital
capacity; MID, minimal important difference; mMRC, modified Medical Research Council; RV, residual volume; SGRQ, St George’s
Respiratory Questionnaire; TLC, total lung capacity.
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years reported that clinical parameters like SGRQ
declined in both the treatment and control group.20 To
estimate the natural rate of functional decline in our
patients, we collected all available pre-treatment
spirometries. We found that the rate of decline did not
change after the LVR-coil treatment but that treat-
ment increased FEV1 to the extent that return to
pre-treatment baseline levels occurred only after
approximately 3 years (Fig. 3). That the rate of decline
did not change is unsurprising; two other studies
investigating LVRS also showed that the rate of
decline after surgery was comparable with the rate of
decline before surgery.21,22
We believe it is as important to evaluate clinical
significance as it is with statistical significance of out-
comes from treatment. Therefore, we also investi-
gated whether patients reached the MID for FEV1, RV,
6MWD and SGRQ at each time point. However, a con-
founding factor is that most MIDs were calculated for
short-term changes, ranging from 115 to 616 months
post-intervention. A long-term MID (for example 3
years) could be lower than an MID for the short term.
Therefore, the MIDs used in our analyses could
underestimate the number of meaningful responders
at 3 years. Unfortunately, this is not known and would
be interesting to investigate. We did not find any pre-
dictive factors to identify responders at 3-year follow-
up. However, our sample size was too small to be able
to evaluate this in detail. Current ongoing large
randomized controlled trials (NCT01608490 and
NCT01822795) will possibly give more insight in the
best responder profile for this treatment.
Long-term follow-up after BLVR with coils has not
been investigated before. A few other studies investi-
gating other LVR techniques included at least 12
months follow-up.The NETT study20 found that 20% of
the patients improved more than 8 points on the SGRQ
total score 3 years after LVRS (patients who died or
were lost to follow-up were considered not improved).
When we apply the same rules for improvement, 31%
of our patients (n = 11) improved more than 8 points
after 3 year. As in our study, the NETT study also found
a larger improvement in the quality of life in the long
term than in exercise capacity. Another study investi-
gated the effect of lung sealant therapy for emphysema
in 16 patients 2 years after the initial treatment.23 They
found a much higher number of patients who reached
the MID for FEV1 2 years after the treatment, which is
50% compared with 19% in our population. Not much
literature to date has been published on longer-term
follow-up data for bronchoscopic LVR devices. Three
small cohort studies investigated long-term follow-up
Figure 3 Decline in forced expiratory volume in 1 s (FEV1) before and after the LVR-coil treatment. Baseline and post-treatment FEV1
shown as mean (±standard deviation). ‘ ’: before treatment; ‘ ’: trend line; ‘ ’: during study participation.
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of endobronchial valve treatment. Venuta et al.24
showed promising results after 3 and 5 years follow-up.
Unfortunately, patient loss to follow-up was not taken
into account, and paired statistical analyses were not
used, making the result difficult to interpret. A retro-
spective study by Kotecha et al.25 showed that 6 out of
16 patients (38%) had sustained long-term improve-
ments in FEV1 (Δ > 0), which is comparable with our
study (at 2-year follow-up:11/27 (31%)). Furthermore,
Hopkinson et al.26 showed that the occurrence of
atelectasis following endobronchial valve treatment
was associated with prolonged survival at 6 years
follow-up.
The major disadvantage of our study is the non-
controlled design and possible selection bias of
patients who volunteered for yearly follow-up visits
after participating in one of our pilot studies.
Although a large number of patients did visit our
hospital yearly, the results at 2- and 3-year follow-up
should be interpreted with caution as patients with
worse response could be presumed less likely to
return for follow-up. It would be useful to investigate
the long-term efficacy and safety of the LVR-coil
treatment in a randomized controlled intervention
study with long-term follow-up. Currently, a large
(n = 315) randomized controlled trial with 5-year
follow-up is enrolling patients and will give addi-
tional insight into the long-term effectiveness and
safety of coil treatment (Lung Volume Reduction Coil
Treatment in Patients With Emphysema Study:
NCT01608490).
In conclusion, follow-up of our very first pilot
patients showed that LVR-coil treatment is safe in the
long term, with no late pneumothoraces, coil migra-
tions or unexpected adverse events. Clinical benefit
gradually declines over time; at 3 years post-
treatment, around 50% of the patients maintained
improvement in 6MWD, SGRQ and mMRC.
Figure 4 Histology of transplanted lungs of two patients (photomicrograph, haematoxylin and eosin stain). (a) Low power magni-
fication of lung tissue demonstrating two device imprints (arrows) in the alveolar parenchyma. (b) Higher magnification of the
boxed area in image (a) demonstrating the two device imprints in tissue. At this magnification, it is evident that there is a thin,
compressed capsule of tissue around the imprints with no other significant inflammatory reaction present. This image also
demonstrates the presence of interstitial fibrosis of alveolar septa along the left hand side of the image. (c) Higher magnification
of the boxed area in image (b) demonstrating a closer view of the device capsule and the surrounding alveolar parenchyma. (d) Low
power magnification of a single device imprint in the alveolar parenchyma (arrow). The imprint is surrounded by a well-organized
fibrous capsule comprised of compressed, concentric rings of stroma. Pre-existing emphysema (enlarged alveolar spaces) is
also evident in this image. (e) Low power magnification of a single device imprint (arrow) in the alveolar parenchyma adjacent
to a pulmonary vein. (f) Low power magnification of a single device imprint in an area of more dense fibrous tissue. The device
capsule contains a mild degree of inflammation. (a–c) Patient 1 year after LVR-coil treatment; (d–f) patient 4 years after LVR-coil
treatment.
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